about
Shiga toxin pathogenesis: kidney complications and renal failure.Thrombotic microangiopathy and associated renal disorders.Circulating microRNAs in patients with Shiga-Toxin-producing E. coli O104:H4 induced hemolytic uremic syndrome.The antimicrobial peptide cathelicidin protects mice from Escherichia coli O157:H7-mediated disease.Role of vascular endothelial growth factor and angiopoietin 1 in renal injury in hemolytic uremic syndrome.Multifaceted hemolytic uremic syndrome in pediatrics.Secondary, profound, sensorineural hearing loss after recovery from haemolytic uraemic syndrome due to enterohaemorrhagic Escherichia coli, and subsequent cochlear implantation, in two Japanese children.The role of the antimicrobial peptide cathelicidin in renal diseases.Role of Shiga/Vero toxins in pathogenesisThe efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice.Soluble plasma VE-cadherin concentrations are elevated in patients with STEC infection and haemolytic uraemic syndrome: a case-control studyEspP, an Extracellular Serine Protease from Enterohemorrhagic E. coli, Reduces Coagulation Factor Activities, Reduces Clot Strength, and Promotes Clot LysisButyrate upregulates endogenous host defense peptides to enhance disease resistance in piglets via histone deacetylase inhibition.Ouabain protects against Shiga toxin-triggered apoptosis by reversing the imbalance between Bax and Bcl-xL.Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature.Diagnostic approach to microangiopathic hemolytic disorders.Incidence and index of severity of hemolytic uremic syndrome in a 26 year period in Fukushima Prefecture, Japan.Efficacy of recombinant human soluble thrombomodulin for childhood hemolytic uremic syndrome.
P2860
Q33397541-285069DC-BF7F-4955-BED4-818DA02F6528Q33402372-D3C030F8-A476-424C-9C74-6AB6190D313FQ33403833-0392A57B-C8D2-489F-A77C-947ED80CE193Q33403877-2227FB1C-381F-4A09-89AB-0E01EA648496Q33404500-53C90E48-EA20-44EA-96E6-B59BE38E7964Q33405452-FADE2059-D1A6-4284-B815-87248B1BEE5DQ33405856-0936BADB-1FDE-4B2A-9525-323989E45654Q33417340-44C83C6A-601A-4203-9A40-E809176C0DDFQ33419440-8ED9A54D-D664-4415-B2BE-35FD86DB7C3AQ33420531-B88BE7B5-11B2-45EF-B915-B077763DD6D0Q33421074-8105CF5C-F5AB-4252-A169-4F0BC113C80DQ33430429-B9FD0B7D-1FD8-4C39-BDB9-F11599C4B7A2Q36941333-C04B53D2-F4CA-42A8-A059-792920DD27F5Q37119923-84B7E6A9-2820-4993-B864-450B831CE5CCQ38024274-8095DAEB-E163-42EA-A6EB-12AC5F1D787CQ39266338-F1C607D4-7FF0-486C-A2D2-2254E7F1DDE4Q51375879-C5E880DD-DDB6-412B-BF51-B0E691E04B8DQ54302067-FFA8E656-B9B0-4FF9-BE66-549C849D5C25
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pathophysiology of typical hemolytic uremic syndrome.
@ast
Pathophysiology of typical hemolytic uremic syndrome.
@en
type
label
Pathophysiology of typical hemolytic uremic syndrome.
@ast
Pathophysiology of typical hemolytic uremic syndrome.
@en
prefLabel
Pathophysiology of typical hemolytic uremic syndrome.
@ast
Pathophysiology of typical hemolytic uremic syndrome.
@en
P356
P1476
Pathophysiology of typical hemolytic uremic syndrome.
@en
P2093
Lisa Sartz
Sally Johnson
P304
P356
10.1055/S-0030-1262879
P577
2010-09-23T00:00:00Z